（进博故事）医疗创新“进博速度”：从进博首秀到落地县乡

Core Viewpoint - The global smallest heart pacemaker, Micra, developed by Medtronic, has gained significant attention and market access in China through the China International Import Expo (CIIE) since its debut in 2018 [1][3]. Group 1: Product Introduction and Market Impact - Micra heart pacemaker was officially launched in China after receiving approval from the National Medical Products Administration in 2019 [1]. - Medtronic has showcased approximately 500 leading therapies at the CIIE, with over 70 being global, Asia-Pacific, or China debuts, resulting in more than 30 star products benefiting from the expo [4]. - Since its launch, Micra has been implemented in over 900 hospitals across China, demonstrating a successful transition from exhibition to clinical application [4]. Group 2: Patient Impact and Clinical Adoption - The CIIE has facilitated direct communication between patients and medical technology companies, allowing patients to learn about innovative therapies that are not yet available in China [3]. - A notable case involved a young patient who, after learning about Micra at the expo, successfully underwent implantation and returned to a normal life, even engaging in extreme sports [3]. - The clinical adoption of Micra has seen a projected increase to over 5,000 implantations nationwide by 2024, showcasing its rapid growth from debut to widespread application [5]. Group 3: Broader Industry Implications - The CIIE serves as a bridge for demand matching in the healthcare sector, enabling Medtronic to align its innovations with the actual needs of the Chinese medical system [5]. - Medtronic's strategy focuses on penetrating lower-tier markets, enhancing collaboration with local healthcare providers, and facilitating the rapid deployment of lightweight medical solutions [7]. - The expo has broken down barriers in the circulation of medical resources, supporting the integration of multinational companies into the Chinese market and promoting high-quality development in the pharmaceutical and healthcare industries [7].